ISRG News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

IS

Mkt Cap

$138.95B

Volume

2.10M

Next Earnings

October 20th

Chart Financials Earnings News About Insider Filings

Should You Buy Medtronic Stock as Its Hugo Surgical Robot Gains Ground?Medtronic's stock is down 3% this year despite strong fundamentals, presenting a buying opportunity for growth-oriented investors. The company's Hugo robotic-assisted surgery system is gaining traction and eroding competitor Intuitive Surgical's market dominance. With Q1 FY2027 revenue up 13.7% YoY, raised full-year guidance, a near-Dividend King status (49 consecutive years of dividend increases), and attractive valuation metrics, analysts view the stock as undervalued compared to peers.The Motley Fool · Sep 17, 2026

ISRG's da Vinci Study Shows Better Outcomes Across 13 Common ConditionsIntuitive Surgical published a large meta-analysis in Annals of Surgery Open showing da Vinci robotic-assisted surgery delivered significant perioperative improvements across 13 benign procedures compared to laparoscopic and open surgery. Results included 54% lower conversion to open surgery, 69% reduction in blood transfusions versus open surgery, and 46% fewer 30-day complications. The da Vinci 5 platform continues gaining momentum with over 1,700 systems installed. ISRG stock gained ~8% following the announcement and currently holds a Zacks Rank #3 (Hold).Zacks Investment Research · Sep 15, 2026

Intuitive Surgical, Inc. (ISRG) Rises As Market Takes a Dip: Key FactsIntuitive Surgical (ISRG) gained 2.38% to $377.94 on September 14, 2026, outperforming a declining broader market. The company is expected to report EPS of $2.61 (up 8.75% YoY) and quarterly revenue of $2.88 billion (up 14.98% YoY). However, the stock has declined 6.43% over the past month and carries a Zacks Rank #3 (Hold) rating with a premium valuation at 34.39 Forward P/E versus the industry average of 21.78.Zacks Investment Research · Sep 14, 2026

Wall Street Isn't Talking About High-Yield Medtronic Stock -- Here's Why It Should BeMedtronic has undergone strategic restructuring by exiting less profitable businesses and investing in new technologies like its Hugo surgical robot. The company reported its highest annual revenue growth in a decade in fiscal 2026, with Q1 FY2027 revenues jumping 13.7% and management raising full-year guidance. With a 3.08% dividend yield and 48-year dividend increase streak, the stock has risen 15% in three months but remains 30% below its 2021 high, suggesting potential upside for dividend investors.The Motley Fool · Sep 9, 2026

The Zacks Analyst Blog Highlights FANUY, ABBNY, KYCCF, NVDA, ISRG, ILMN, NOVT, BOTZ, ROBO, ROBT and IBOTZacks highlights the robotics and AI sector as a major growth opportunity, with the general-purpose robotics market projected to grow from under $1 billion in 2025 to $370 billion by 2040. The article examines key industry players including Fanuc, ABB, Keyence, NVIDIA, Intuitive Surgical, and Illumina, and recommends four robotics-focused ETFs (BOTZ, ROBO, ROBT, IBOT) as diversified investment vehicles to capitalize on this trend.Zacks Investment Research · Sep 8, 2026

Intuitive Surgical's Growth Has Cooled From Its Post-Pandemic Highs. Is That a Buying Opportunity or a Warning?Intuitive Surgical's stock has declined 40% from recent highs amid slowing da Vinci robot sales growth due to increased competition from Medtronic and Johnson & Johnson. However, the company's core business model relies on recurring revenue from parts and services (75% of revenue), which provides stable annuity-like income streams. With valuation metrics below five-year averages and continued AI opportunities, the stock may represent a buying opportunity for aggressive growth investors despite its historical volatility.The Motley Fool · Sep 5, 2026

2 Stocks Down 8% or More That Are Screaming Buys Right NowThe article highlights two beaten-down stocks as potential buying opportunities: Intuitive Surgical, down 34% year-to-date, is positioned to benefit from its da Vinci 5 surgical system's advanced features and expanding market; Novo Nordisk, down 8% this year, has promising GLP-1 pipeline candidates like amycretin and UBT251 that could help it regain market share in the weight-loss drug sector.The Motley Fool · Sep 4, 2026

3 Stocks Whose Competitive Walls Tower Over Nvidia'sWhile Nvidia has built a strong competitive moat in AI chips, three healthcare stocks—Moderna, Intuitive Surgical, and Vertex Pharmaceuticals—possess even more formidable competitive advantages. Moderna leverages its mRNA expertise across vaccines and oncology; Intuitive Surgical dominates robotic surgery with high switching costs; and Vertex leads in cystic fibrosis treatment with a patent-protected pipeline extending to the late 2030s.The Motley Fool · Sep 3, 2026

Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?The iShares U.S. Medical Devices ETF (IHI) is reviewed as a passively managed fund offering diversified exposure to the healthcare medical devices sector. With $3.44 billion in assets and a 0.37% expense ratio, IHI tracks the Dow Jones U.S. Select Medical Equipment Index. The fund has declined 12.46% year-to-date and carries a Zacks ETF Rank of 3 (Hold), making it a reasonable but not exceptional choice for sector exposure.Zacks Investment Research · Sep 2, 2026

Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?Intuitive Surgical is prioritizing R&D investment over near-term profitability to drive long-term growth, focusing on AI/ML, robotics, and expanding into new clinical areas like GI, cardiac, and lung procedures. The company is sacrificing near-term expense leverage to build competitive moats and broaden its addressable market. Peer companies Edwards Lifesciences and Glaukos are similarly investing heavily in R&D to strengthen their competitive positions.Zacks Investment Research · Sep 1, 2026

IS

ISRGIntuitive Surgical Inc.

ISRG

Pay with—

Available Balance0.00

Your PositionYou don't own any ISRG yet.

Related Tickers

Earnings